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Background
Antigen-presenting dendritic cells (DC) present viral anti-
gens to T-cells after uptake of apoptotic bodies derived
from virus-infected cells. Besides, processing and presen-
tation of ingested antigen, DC were recently shown to be
able to incorporate part of the DNA from the apoptotic
cells into their own chromosomes and express the
encoded antigens. This mechanism could lead to a more
efficient presentation of foreign antigens and activation of
antigen specific naive T-cells. It was recently exploited for
induction of HIV specific immune responses in a HIV-1/
MuLV mouse infection model.
Methods
Here we have evaluated the safety and immunogenicity of
this approach in non human primates using autologous
activated T-cells infected with replication defective VSV
pseudotyped SIVΔenv. Animals were immunized by intra-
dermal injection of 50 to 200 million cells, irradiated with
a 150 Gy dose for apoptosis induction prior to immuniza-
tion.
Results
SIV Gag specific cellular immune responses were induced
already after the first immunization in 3 out of 6 animals
with a strong bias towards IFNγ and IL-2 production,
while no IL-4 production was found. SIV Gag specific anti-
body responses were observed in five out of six animals.
Conclusion
These finding underscore the potential application of this
strategy in therapeutic as well as prophylactic vaccination
against HIV-1 as well as other pathogens or as a cancer
therapeutic.
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